GSK acquires full rights to develop, manufacture and commercialise globally mRNA candidate vaccines for influenza and COVID-19, including combinations
Tag: COVID-19
AstraZeneca reports strong growth in 2023 despite COVID-19 challenges
AstraZeneca, a global biopharmaceutical company, announced its financial results for the full year 2023, showing a 6% increase in total revenue and a 15% increase in core earnings per share. The company’s total revenue reached $45,811 million, up from $43,075 million in 2022, despite a decline of $3,736 million from COVID-19 medicines. Excluding COVID-19 medicines,…
Data shows SARS-CoV-2 human challenge studies safe in healthy young adults
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces the results from the world’s first COVID-19 characterisation study, which was a partnership between hVIVO, Imperial College London, the Vaccine Taskforce and Department of Health and Social Care…
Pakistanis can’t meet life-goals due to ‘Confidence Gap’
Standard Chartered latest survey into affluent (comprising emerging affluent, affluent and high net worth) consumers in 12 markets across Asia, Africa, the Middle East and UK, revealed that in Pakistan 92 per cent of them have reset their life goals following the pandemic. At the same time, for 50 per cent of the respondents, COVID-19…
Spiritus Mundi intends IPO on London Stock Exchange
LONDON, UK: Special purpose acquisition vehicle, Spiritus Mundi, intends to launch an initial public offering (IPO) on the Main Market of the London Stock Exchange. Spiritus Mundi was established in 2021 as a special purpose acquisition vehicle which will seek acquisition targets in Europe and Asia in the clinical diagnostics sector. The Company will seek…
Kingmaker Footwear resumes production at Vietnam factory
HONG KONG: Kingmaker Footwear Holdings Limited has resumed production at the group’s factory in Binh Duong Province, Vietnam. Kingmaker Footwear had earlier notified temporary production halt at the factory after the report of local COVID-19 cases. The Board advised the shareholders and potential investors of the Company that, after satisfying all reopening conditions imposed by the local…
LNG demand set for growth as global economies recover
LONDON: Global liquefied natural gas (LNG) trade increased to 360 million tonnes in 2020, according to Shell’s latest annual LNG Outlook published today, despite the unprecedented volatility caused by the COVID-19 pandemic which resulted in lockdowns around the world. Though marginal, the increase in volume reflects the resilience and flexibility of the global LNG market…
Property and casualty insurers report 27.5% drop in net income during first nine months of 2020
JERSEY CITY: The private U.S. property and casualty (P&C) insurance industry’s net income after taxes dropped 27.5 percent to $35.1 billion in the first nine months of 2020 and net underwriting gains declined to $0.3 billion, from $5.4 billion a year earlier. In the first nine months of 2020, the private U.S. property and casualty…
U.S. FDA approves Gilead’s antiviral Veklury (remdesivir) for treatment of COVID-19
FOSTER CITY: Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the antiviral drug Veklury (remdesivir) for the treatment of patients with COVID-19 requiring hospitalization. As an antiviral drug, Veklury works to stop replication of SARS-CoV-2, the virus that causes COVID-19. Previously authorized by the FDA for emergency use…
AstraZeneca’s COVID-19 long-acting antibody combination advances into Phase III clinical trials
LONDON: AstraZeneca’s long-acting antibody (LAAB) combination, AZD7442, will advance into two Phase III clinical trials in more than 6,000 participants at sites in and outside the US that are due to begin in the next weeks, a news release said. AstraZeneca has received support of around $486 million from the US Government for the development…
Oncimmune announces UK Government funding for tool for use in COVID-19
LONDON: Oncimmune Holdings announced the award of funding from the ‘UK Research and Innovation (UKRI) Ideas to Address COVID-19’ programme, to support a joint collaboration between Oncimmune and Medicines Discovery Catapult to deliver the IMmunity Profiling of pAtients with COVID-19 for Therapy and Triage (IMPACTT) programme. This collaboration represents a critical partnership in response to…
Synairgen and Clinigen sign agreement for treatment of hospitalised patients with COVID-19
SOUTHAMPTON: Synairgen plc and Clinigen Group have signed an agreement to launch a Managed Access Program for Synairgen’s inhaled formulation of interferon beta (IFN-beta), SNG001, in the UK and the EU for the treatment of hospitalised COVID-19 patients. SNG001 is an inhaled formulation of IFN-beta for direct delivery to the lungs via nebulisation. Synairgen announced…